Do All Drug Products Need a Nitrosamine Risk Assessment? FDA’s Risk-Based Approach Explained
Assessing the chemical safety of human drug products requires a thorough understanding of potential mutagenic and carcinogenic impurities that fall […]
Nitrosamine Risk Assessment and Testing Services for NDA and BLA Submissions
Introduction: Nitrosamine impurities are among the most scrutinized safety concerns in modern pharmaceutical development, and no NDA or BLA submission
Nitrosamine Risk Assessment and Testing Services for NDA and BLA Submissions Read More »
Nitrosamine Testing for Inhalation Drug Products: MDIs, DPIs, and Nasal Sprays
Introduction: Nitrosamine Testing Inhalation Drug Products MDI DPI Nasal Spray has become a critical focus area for pharmaceutical manufacturers after
Nitrosamine Testing for Inhalation Drug Products: MDIs, DPIs, and Nasal Sprays Read More »
In Silico Potency Prediction for NDSRIs: Using SAR, DEREK, and CASE Ultra for Hazard Classification
Introduction: Why Conventional Mutagenicity Models Are Inadequate for NDSRIs The regulatory complexity associated with N-Nitrosamine Drug Substance-Related Impurities (NDSRIs) extends
Nitrosamine Formation Pathways in API Synthesis: How Chemistry Decisions Create Impurity Risk
Introduction: When the Synthesis Route Itself Becomes the Problem The pharmaceutical industry’s encounter with nitrosamine contamination has revealed an important
What Are Nitrosamines? Formation Mechanisms, Types, and Health Risks Explained
Introduction Understanding What Are Nitrosamines is essential when evaluating the chemical safety, purity, and structural stability of raw materials, water
What Are Nitrosamines? Formation Mechanisms, Types, and Health Risks Explained Read More »
Nitrosamine Risk Assessment and Testing in ANDA Submissions: Regulatory Expectations
Introduction: Nitrosamine risk assessment and Nitrosamine Testing in ANDA Submissions refer to the regulatory process used to identify, measure, and
Nitrosamine Risk Assessment and Testing in ANDA Submissions: Regulatory Expectations Read More »
How to Respond to a Regulatory Query on Nitrosamine Risk Assessment
Introduction Pharmaceutical companies often receive regulatory questions about nitrosamine impurities during submissions, variations, or post-approval reviews. When this happens, organizations
How to Respond to a Regulatory Query on Nitrosamine Risk Assessment Read More »
Nitrosamine Risk in Solid Oral Dosage vs Liquid Formulations: Comparative Analysis
Introduction The Nitrosamine Risk in Solid vs Liquid Dosage forms has become a critical topic in pharmaceutical quality and regulatory
Nitrosamine Risk in Solid Oral Dosage vs Liquid Formulations: Comparative Analysis Read More »
Trending Nitrosamine Recalls: Lessons Learned from Global Regulatory Actions
Introduction: In recent years, the pharmaceutical industry has faced several major product recalls linked to nitrosamine contamination. A detailed Nitrosamine
Trending Nitrosamine Recalls: Lessons Learned from Global Regulatory Actions Read More »